Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 3/2008

01-06-2008

Systemic Lupus Erythematosus Involving the Nervous System: Presentation, Pathogenesis, and Management

Author: Julia J. Rhiannon

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2008

Login to get access

Abstract

Neuropsychiatric syndromes in systemic lupus erythematosus (SLE) have a wide range of severity and phenotype and are fairly common. Presentations are seen involving both central and peripheral nervous systems. Pathogenic mechanisms are thought to include vascular occlusion and hemorrhage, antineuronal antibodies, cytokine effects, choroid plexus dysfunction, neuroendocrine–immune effects, and direct central nervous system (CNS) tissue injury. Work-up includes serum, cerebrospinal fluid (CSF), and imaging studies. Treatment is based on severity and phenotype and includes steroids, anticoagulants, antidepressants, and cytotoxic approaches. Much remains to be done in terms of further elucidation of pathologic processes, correlation of these mechanisms with specific phenotypes, and management of the most severe presentations of neuropsychiatric lupus erythematosus.
Literature
1.
go back to reference Stojanovich L et al (2007) Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev 6:421–426PubMedCrossRef Stojanovich L et al (2007) Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev 6:421–426PubMedCrossRef
2.
go back to reference West S (2006) Systemic lupus erythematosus and the nervous system. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 6th edn. Lippincott, Williams and Wilkins, Philadelphia, p 707–736 West S (2006) Systemic lupus erythematosus and the nervous system. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 6th edn. Lippincott, Williams and Wilkins, Philadelphia, p 707–736
3.
go back to reference Ahrens D et al (1996) Expression of matrix metalloproteinase 9 (96kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 39(9):1576–1587PubMedCrossRef Ahrens D et al (1996) Expression of matrix metalloproteinase 9 (96kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 39(9):1576–1587PubMedCrossRef
4.
go back to reference Matsukawa Y et al (1994) Suicide in patients with systemic lupus erythematosus: a clinical analysis of seven suicidal patients. Lupus 3(1):31–35PubMedCrossRef Matsukawa Y et al (1994) Suicide in patients with systemic lupus erythematosus: a clinical analysis of seven suicidal patients. Lupus 3(1):31–35PubMedCrossRef
5.
go back to reference Karassa F et al (2003) Suicide attempts in patients with systemic lupus erythematosus. Ann Rheum Dis 62(1):58–60PubMedCrossRef Karassa F et al (2003) Suicide attempts in patients with systemic lupus erythematosus. Ann Rheum Dis 62(1):58–60PubMedCrossRef
6.
go back to reference Sullivan-Marx E et al (2001) Delirium. In: Maddox G (ed) The encyclopedia of aging, 3rd edn. Springer, New York, NY Sullivan-Marx E et al (2001) Delirium. In: Maddox G (ed) The encyclopedia of aging, 3rd edn. Springer, New York, NY
7.
go back to reference Jennekens F et al (2002) The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology 41(6):605–618PubMedCrossRef Jennekens F et al (2002) The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology 41(6):605–618PubMedCrossRef
8.
go back to reference Pompei P et al (1994) Delirium in hospitalized older persons: outcomes and predictors. J Am Geriatr Soc 42(8):809–815PubMed Pompei P et al (1994) Delirium in hospitalized older persons: outcomes and predictors. J Am Geriatr Soc 42(8):809–815PubMed
9.
go back to reference Kotzin BL, Kozora E (2001) Anti-DNA meets NMDA in neuropsychiatric lupus. Nat Med 7(11):1175–1176PubMedCrossRef Kotzin BL, Kozora E (2001) Anti-DNA meets NMDA in neuropsychiatric lupus. Nat Med 7(11):1175–1176PubMedCrossRef
10.
go back to reference Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, Diamond B (2006) Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci 103(52):19854–19859PubMedCrossRef Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, Diamond B (2006) Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci 103(52):19854–19859PubMedCrossRef
11.
go back to reference Wekking E et al (1991) Cognitive and emotional disturbances in systemic lupus erythematosus. Psychother Psychosom 55(2–4):126–131PubMedCrossRef Wekking E et al (1991) Cognitive and emotional disturbances in systemic lupus erythematosus. Psychother Psychosom 55(2–4):126–131PubMedCrossRef
12.
go back to reference Ginsburg K et al (1992) A controlled study of the prevalence of cognitive dysfunction in randomly selected patients with systemic lupus erythematosus. Arthritis Rheum 35(7):776–782PubMedCrossRef Ginsburg K et al (1992) A controlled study of the prevalence of cognitive dysfunction in randomly selected patients with systemic lupus erythematosus. Arthritis Rheum 35(7):776–782PubMedCrossRef
13.
go back to reference Kiss E, Shoenfeld Y (2007) Are anti-ribosomal p protein antibodies relevant in systemic lupus erythematosus? Clin Rev Allergy Immunol 32(1):37–46PubMed Kiss E, Shoenfeld Y (2007) Are anti-ribosomal p protein antibodies relevant in systemic lupus erythematosus? Clin Rev Allergy Immunol 32(1):37–46PubMed
14.
go back to reference Shoenfeld Y et al (2007) To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. J Autoimmun 28(2–3):165–169PubMedCrossRef Shoenfeld Y et al (2007) To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. J Autoimmun 28(2–3):165–169PubMedCrossRef
15.
go back to reference Toubi E, Shoenfeld Y (2007) Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 6(3):119–125PubMedCrossRef Toubi E, Shoenfeld Y (2007) Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 6(3):119–125PubMedCrossRef
16.
go back to reference Sun KH et al (2005) Monoclonal ribosomal P autoantibody inhibits the expression and release of IL-12, TNF-α and iNOS in activated RAW macrophage cell line. J Autoimmun 24:135–143PubMedCrossRef Sun KH et al (2005) Monoclonal ribosomal P autoantibody inhibits the expression and release of IL-12, TNF-α and iNOS in activated RAW macrophage cell line. J Autoimmun 24:135–143PubMedCrossRef
17.
go back to reference Strous RD, Shoenfeld Y (2006) To smell the immune system: olfaction, autoimmunity and brain involvement. Autoimmun Rev 6:54–60PubMedCrossRef Strous RD, Shoenfeld Y (2006) To smell the immune system: olfaction, autoimmunity and brain involvement. Autoimmun Rev 6:54–60PubMedCrossRef
18.
go back to reference Muscal E, Myones B (2007) The role of autoantibodies in pediatric neuropsychiatric systemic lupus erythematosus. Autoimmun Rev 6(4):215–217PubMedCrossRef Muscal E, Myones B (2007) The role of autoantibodies in pediatric neuropsychiatric systemic lupus erythematosus. Autoimmun Rev 6(4):215–217PubMedCrossRef
19.
go back to reference Cavazzana I et al (2007) Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? J Autoimmun 28(2–3):160–164PubMedCrossRef Cavazzana I et al (2007) Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? J Autoimmun 28(2–3):160–164PubMedCrossRef
20.
go back to reference Kozora E et al (2001) Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. J Int Neuropsychol Soc 7(6):745–754PubMedCrossRef Kozora E et al (2001) Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. J Int Neuropsychol Soc 7(6):745–754PubMedCrossRef
21.
go back to reference Hanly J et al (1997) Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum 40(8):1542–1543PubMedCrossRef Hanly J et al (1997) Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum 40(8):1542–1543PubMedCrossRef
22.
go back to reference Loukkola J et al (2003) Cognitive impairment in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus: a population-based neuropsychological study. J Clin Exp Neuropsychol 25(1):145–151PubMedCrossRef Loukkola J et al (2003) Cognitive impairment in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus: a population-based neuropsychological study. J Clin Exp Neuropsychol 25(1):145–151PubMedCrossRef
23.
go back to reference Rao S (2004) Cognitive function in patients with multiple sclerosis: impairment and treatment. Int J M S Care 6(1):9–22 Rao S (2004) Cognitive function in patients with multiple sclerosis: impairment and treatment. Int J M S Care 6(1):9–22
24.
go back to reference Ishikura R et al (2001) Factors associated with anxiety, depression and suicide ideation in female outpatients with SLE in Japan. Clin Rheumatol 20(6):394–400PubMedCrossRef Ishikura R et al (2001) Factors associated with anxiety, depression and suicide ideation in female outpatients with SLE in Japan. Clin Rheumatol 20(6):394–400PubMedCrossRef
25.
go back to reference Denburg J et al (1987) Neuronal antibodies and cognitive function in systemic lupus erythematosus. Neurology 37(3):464–467PubMed Denburg J et al (1987) Neuronal antibodies and cognitive function in systemic lupus erythematosus. Neurology 37(3):464–467PubMed
26.
go back to reference Fragoso-Loyo H et al (2007) Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 56(4):1242–1250PubMedCrossRef Fragoso-Loyo H et al (2007) Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 56(4):1242–1250PubMedCrossRef
27.
go back to reference Stoppe G et al (1990) Positron emission tomography in neuropsychiatric lupus erythematosus. Neurology 40(2):304–308PubMed Stoppe G et al (1990) Positron emission tomography in neuropsychiatric lupus erythematosus. Neurology 40(2):304–308PubMed
28.
go back to reference Weiner S et al (2000) Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 59(5):377–385PubMedCrossRef Weiner S et al (2000) Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 59(5):377–385PubMedCrossRef
29.
go back to reference Watreloo K et al (2002) Neurospychological function in systemic lupus erythematosus: a five-year longitudinal study. Rheumatology 41(4):411–415CrossRef Watreloo K et al (2002) Neurospychological function in systemic lupus erythematosus: a five-year longitudinal study. Rheumatology 41(4):411–415CrossRef
30.
go back to reference Carlomagno S et al (2000) Cognitive impairment in systemic lupus erythematosus: a follow-up study. J Neurol 247(4):273–279PubMedCrossRef Carlomagno S et al (2000) Cognitive impairment in systemic lupus erythematosus: a follow-up study. J Neurol 247(4):273–279PubMedCrossRef
31.
go back to reference Carbotte R et al (1995) Cognitive dysfunction in systemic lupus erythematosus is independent of active disease. J Rheumatology 22:863–867 Carbotte R et al (1995) Cognitive dysfunction in systemic lupus erythematosus is independent of active disease. J Rheumatology 22:863–867
32.
go back to reference Denburg S et al (1997) Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self-report. J Rheumatology 24:998–1003 Denburg S et al (1997) Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self-report. J Rheumatology 24:998–1003
33.
go back to reference Gonzales-Crespo M et al (1995) Magnetic resonance imaging of the brain in systemic lupus erythematosus. Br J Rheumatology 34(11):1055–1060CrossRef Gonzales-Crespo M et al (1995) Magnetic resonance imaging of the brain in systemic lupus erythematosus. Br J Rheumatology 34(11):1055–1060CrossRef
34.
go back to reference Monastero R et al (2001) Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. Neurol Sci 184:33–39CrossRef Monastero R et al (2001) Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. Neurol Sci 184:33–39CrossRef
35.
go back to reference Denburg S et al (1987) Cognitive impairment in systemic lupus erythematosus: a neuropsychological study of individual and group deficits. J Clin Exp Neuropsychol 9(4):323–339PubMedCrossRef Denburg S et al (1987) Cognitive impairment in systemic lupus erythematosus: a neuropsychological study of individual and group deficits. J Clin Exp Neuropsychol 9(4):323–339PubMedCrossRef
36.
go back to reference Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28(2–3):69–75PubMedCrossRef Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28(2–3):69–75PubMedCrossRef
37.
38.
go back to reference Holvast B, Huckriede A, Kallenberg CG, Bijl M (2007) Influenza vaccination in systemic lupus erythematosus: safe and protective? Autoimmun Rev 6(5):300–305PubMedCrossRef Holvast B, Huckriede A, Kallenberg CG, Bijl M (2007) Influenza vaccination in systemic lupus erythematosus: safe and protective? Autoimmun Rev 6(5):300–305PubMedCrossRef
39.
go back to reference Elkayam O, Ablin J, Caspi D (2007) Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev 6(5):312–314PubMedCrossRef Elkayam O, Ablin J, Caspi D (2007) Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev 6(5):312–314PubMedCrossRef
40.
go back to reference Koike T, Bohgaki M, Amengual O, Atsumi T (2007) Antiphospholipid antibodies: lessons from the bench. J Autoimmun 28(2–3):129–133PubMedCrossRef Koike T, Bohgaki M, Amengual O, Atsumi T (2007) Antiphospholipid antibodies: lessons from the bench. J Autoimmun 28(2–3):129–133PubMedCrossRef
Metadata
Title
Systemic Lupus Erythematosus Involving the Nervous System: Presentation, Pathogenesis, and Management
Author
Julia J. Rhiannon
Publication date
01-06-2008
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 3/2008
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-007-8052-z

Other articles of this Issue 3/2008

Clinical Reviews in Allergy & Immunology 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.